The current identification of the TP53/SLC7A11/ALOX12 axis as a modulator of DDP sensitivity adds a novel ferroptosis-linked pathway to this compendium of resistance mechanisms, highlighting potential convergent therapeutic strategies targeting key regulatory nodes across different cancers. This evidence concerns the gene TP53 and cancer.